Impact of Biologic Therapies and Multidisciplinary Care in Managing Diabetic Eye Disease

Objective: To evaluate the impact of current and emerging biologic therapies on the treatment of diabetic eye diseases, specifically diabetic retinopathy and diabetic macular edema, and to examine how integrating these therapies with early detection, multidisciplinary collaboration, and patient-centered care improves long-term visual outcomes in patients with diabetes. Background: Diabetic retinopathy (DR) and diabetic macular edema (DME) are among the most common and vision-threatening complications of diabetes mellitus. As global diabetes prevalence continues to rise, so does the burden of diabetic eye disease. Many patients face barriers to care, and substantial gaps remain in treatment accessibility and long-term adherence. Although treatments such as anti-vascular endothelial growth factor (anti-VEGF) agents and corticosteroids have transformed the management of DR and DME, novel therapies may pose challenges, including increased costs or complexity associated with injection administration. A comprehensive, multidisciplinary strategy that integrates biologic therapies with early screening and coordinated care may further improve clinical outcomes and reduce the risk of vision loss in this high-risk population. Methods: This review synthesizes evidence from controlled trials, observational studies, and treatment guidelines published between 2010 and 2025. It evaluates pharmacologic interventions, including anti-VEGF agents and corticosteroids, analyzing their efficacy, dosing strategies, and adverse effects. Various interdisciplinary care models and public health factors, such as screening adherence and access disparities, were examined and summarized. Results: Biologic agents targeting VEGF and inflammatory pathways demonstrate strong efficacy in preserving or improving visual acuity in patients with DME and DR, particularly when administered at individualized intervals. However, high treatment burden, limited adherence, and disparities in access present ongoing challenges. Studies show that early ophthalmologic screening, routine HbA1c monitoring, and collaborative care among healthcare professionals lead to significantly better disease management and reduced progression to vision-threatening stages. Conclusions: The management of diabetic eye disease is undergoing a paradigm shift with the advent of biologic therapies. When coupled with routine screening, patient education, and a multidisciplinary care model, these interventions can substantially improve visual and systemic outcomes in diabetic patients. Ongoing innovations in drug delivery, gene therapy, and integrin-targeting biologics hold additional promise, although increased accessibility and personalized treatment strategies are crucial to ensuring equitable care across diverse populations.